The Food and Drug Administration announced Wednesday its intention to remove oral phenylephrine, a common ingredient in ...

Based on its chemical properties, Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable sustained absorption and efficacy in ...